Merck's Keytruda Survives 'Conflicted' Adcom Vote For Bladder Cancer Indication
Executive Summary
Many Oncologic Drugs Advisory Committee members struggled to decide whether the data showed a clinically meaningful benefit in the proposed bladder cancer indication.